Embryonal rhabdomyosarcoma of the prostate in a young male: A rare case report

被引:6
作者
Alenezi, S. A. A. D. [1 ,3 ]
Zahir, Mohammed [2 ]
Alenezi, Jarah [2 ]
机构
[1] Jaber Alahmad Hosp, Urol Dept, Kuwait, Kuwait
[2] Al Jahra Hosp, Urol Dept, Kuwait, Kuwait
[3] Univ Jordan, Amman, Jordan
关键词
Rhabdomyosarcoma; Prostate; Bladder outlet obstruction; Embryonal rhabdomyosarcoma; Case report; ADULT; DIAGNOSIS; SURVIVAL; THERAPY;
D O I
10.1016/j.ijscr.2023.108228
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction and importance: Embryonal rhabdomyosarcoma (ERMS) of the prostate is a rare disease, and it has a poor prognosis. Mostly patient come with late stage thus with delayed diagnosis and worse outcomes.Case presentation: a 35-year-old Bangladeshi male presented with bladder outlet obstruction in an intermittent pattern.Patient was not complaining from any other urological symptoms, there was no hematuria or dysuria, even no constitutional symptoms, no history of weight loss, no anorexia or night rigors, also there was no history of fever. Patients have an only previous history of spinal screw without any other medical illnesses. Patient came to casualty with frequent visits without any inflammatory markers elevation even with normal biochemical labs. O/E he found to have a prostatic mass on PR examination of which patient admitted to urology department and underwent diagnostic cystoscopy which showed cauliflower mass at the prostatic urethra. Bi-opsies retrieved and showed embryonal rhabdomyosarcoma (RMS) of the prostate under the histopathological examination.Clinical discussion: Embryonal rhabdomyosarcoma (ERMS) mostly care a poor prognosis and modalities vary according to the presentation and the stage. However distant metastasis is common at the time of presentation.Conclusion: embryonal rhabdomyosarcoma of the prostate is a rare and aggressive tumor with a low survival rate in adults. However, more clinical data needed for a better outcome.
引用
收藏
页数:4
相关论文
共 12 条
[1]   The SCARE 2018 statement: Updating consensus Surgical CAse REport (SCARE) guidelines [J].
Agha, Riaz A. ;
Borrelli, Mimi R. ;
Farwana, Reem ;
Koshy, Kiron ;
Fowler, Alexander J. ;
Orgill, Dennis P. ;
Zhu, Hongyi ;
Alsawadi, Abdulrahman ;
Noureldin, Ashraf ;
Rao, Ashwini ;
Enam, Ather ;
Thoma, Achilleas ;
Bashashati, Mohammad ;
Vasudevan, Baskaran ;
Beamish, Andrew ;
Challacombe, Ben ;
De Wilde, Rudy Leon ;
Machado-Aranda, David ;
Laskin, Daniel ;
Muzumdar, Dattatraya ;
D'cruz, Anil ;
Manning, Todd ;
Healy, Donagh ;
Pagano, Duilio ;
Goel, Prabudh ;
Ranganathan, Priya ;
Pai, Prathamesh S. ;
Raja, Shahzad ;
Athe, M. Hammad ;
Kadioazlu, Huseyin ;
Nixon, Iain ;
Mukherjee, Indraneil ;
Gomez Riva, Juan ;
Raveendran, Kandiah ;
Derbyshire, Laura ;
Valmasoni, Michele ;
Chalkoo, Mushtaq ;
Raison, Nicholas ;
Muensterer, Oliver ;
Bradley, Patrick ;
Roberto, Coppola ;
Afifi, Raafat ;
Rosin, David ;
Klappenbach, Roberto ;
Wynn, Rolf ;
Giordano, Salvatore ;
Basu, Somprakas ;
Surani, Salim ;
Suman, Paritosh ;
Thorat, Mangesh .
INTERNATIONAL JOURNAL OF SURGERY, 2018, 60 :132-136
[2]   Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803 [J].
Arndt, Carola A. S. ;
Stoner, Julie A. ;
Hawkins, Douglas S. ;
Rodeberg, David A. ;
Hayes-Jordan, Andrea A. ;
Paidas, Charles N. ;
Parham, David M. ;
Teot, Lisa A. ;
Wharam, Moody D. ;
Breneman, John C. ;
Donaldson, Sarah S. ;
Anderson, James R. ;
Meyer, William H. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) :5182-5188
[3]   Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: The intergroup rhabdomyosarcoma study-IV experience - A report from the soft tissue sarcoma committee of the children's oncology group [J].
Burke, Megan ;
Anderson, James R. ;
Kao, Simon C. ;
Rodeberg, David ;
Qualman, Stephen J. ;
Wolden, Suzanne L. ;
Meyer, William H. ;
Breitfeld, Philip P. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (31) :4909-4913
[4]   Does body mass index at diagnosis or weight change during therapy predict toxicity or survival in intermediate risk rhabdomyosarcoma? A report from the Children's Oncology Group soft tissue sarcoma committee [J].
Burke, Megan E. ;
Lyden, Elizabeth R. ;
Meza, Jane L. ;
Ladas, Elena J. ;
Dasgupta, Roshni ;
Wiegner, Ellen A. ;
Arndt, Carola A. S. .
PEDIATRIC BLOOD & CANCER, 2013, 60 (05) :748-753
[5]   Prostate embryonal rhabdomyosarcoma in adults: Case report and review of literature [J].
Ciammella, Patrizia ;
Galeandro, Maria ;
D'Abbiero, Nunziata ;
Palmieri, Tamara ;
Donini, Elisa ;
Iotti, Cinzia .
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2013, 18 (05) :310-315
[6]  
Clay MR, Embryonal rhabdomyosarcoma
[7]  
Dagher R, 1999, Oncologist, V4, P34
[8]   Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma [J].
Ferrari, Andrea ;
Miceli, Rosalba ;
Meazza, Cristina ;
Casanova, Michela ;
Favini, Francesca ;
Morosi, Carlo ;
Trecate, Giovanna ;
Marchiano, Alfonso ;
Luksch, Roberto ;
Cefalo, Graziella ;
Terenziani, Monica ;
Spreafico, Filippo ;
Polastri, Daniela ;
Podda, Marta ;
Catania, Serena ;
Schiavello, Elisabetta ;
Giannatempo, Patrizia ;
Gandola, Lorenza ;
Massimino, Maura ;
Mariani, Luigi .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) :1322-1328
[9]   Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy [J].
Kojima, Yuki ;
Hashimoto, Kenji ;
Ando, Masashi ;
Yonemori, Kan ;
Hirakawa, Akihiro ;
Kodaira, Makoto ;
Yunokawa, Mayu ;
Shimizu, Chikako ;
Tamura, Kenji ;
Katsumata, Noriyuki ;
Hosono, Ako ;
Makimoto, Atsushi ;
Fujiwara, Yasuhiro .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (07) :1249-1257
[10]   ADULT UROLOGICAL SARCOMA [J].
RUSSO, P ;
BRADY, MS ;
CONLON, K ;
HAJDU, SI ;
FAIR, WR ;
HERR, HW ;
BRENNAN, MF .
JOURNAL OF UROLOGY, 1992, 147 (04) :1032-1037